Peter Lynch fit · Growth at a reasonable price (GARP)
Is Acadia Pharmaceuticals Inc. (ACAD) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
15/100
FPas un fit
3/6 critères validés
Les critères de Peter Lynch, appliqués à ACAD
PEG ≤ 1.0
clé—
EPS CAGR ≥ 15%
clé0.0%
Revenue CAGR ≥ 10%
-22.5%
Net margin > 0
24.9%
Comment ACAD se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$4.65B
PER (TTM)
19.0x
ROIC (TTM)
25.22%
Marge brute
91.92%
Questions fréquentes
What is ACAD's Peter Lynch fit score?
ACAD scores 15/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own ACAD?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ACAD.
How often is this score updated?
ACAD's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande ACAD personnellement.